Burkitt lymphoma (BL) is an aggressive form of B cell lymphoma that can affect children and
adults. The study of BL led to the identification of the first recurrent chromosomal aberration …

Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …

Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding
specificity to CD20. It was the first therapeutic antibody approved for oncology patients and …

Background Treatment with rituximab has improved the outcome for patients with non-
Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Significant advances have been made in the last decade toward a better understanding of
the disease pathogenesis and the development of novel therapies that target specific …

Purpose Interim positron emission tomography (PET) using the tracer,[18F]
fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin …

Background Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin,
calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic …